Dongling Yang

Title: **The Innovations of Dongling Yang in Targeted Drug Delivery**

Introduction

Dongling Yang is an influential inventor based in Beijing, China. He has made significant contributions to the field of drug delivery systems, focusing on the targeted treatment of tumors. With one patented invention to his name, his work exemplifies the intersection of innovative research and practical application in biomedicine.

Latest Patents

Dongling Yang's notable patent is titled "Drug carrier for tumor-specific targeted drug delivery and use thereof." This patent discloses a novel tumor-targeted drug delivery system that consists of a tumor-targeted drug carrier made from full heavy-chain human ferritin. The system allows for enhanced treatment efficacy by delivering a tumor-treating drug directly to the target cells. The patent also encompasses a method for preparing this innovative drug delivery system, which involves depolymerizing polymerized full heavy-chain human ferritin, binding the drug to it, and subsequently re-polymerizing the structure to form nanoparticles.

Career Highlights

Dongling Yang currently works at the Institute of Biophysics, Chinese Academy of Sciences. His research focuses on developing advanced drug delivery systems, which not only improve the effectiveness of cancer treatments but also minimize side effects associated with conventional therapy. His dedication to research is evident in his patent, showcasing his ability to translate scientific knowledge into tangible solutions.

Collaborations

In his pursuit of innovation, Dongling Yang collaborates with esteemed colleagues, including Xiyun Yan and Kelong Fan. These partnerships enhance his research by combining expertise from various fields, contributing to the advancement of targeted drug delivery technologies.

Conclusion

Dongling Yang's work stands as a testament to the power of innovation in the medical field. With his patented drug delivery system, he is paving the way for improved treatment options for cancer patients. As further research and development continue at the Institute of Biophysics, his contributions will likely inspire future breakthroughs in targeted therapeutics.